Final programme - eshre 2013

More documents

Recommendations

Info

COURSE 7Sunday, 7 July−−−−−−Room Capital Hall BOvarian stimulation for ART: how to achieve efficacy and safety?Organised by the Special Interest Group Reproductive EndocrinologyCourse coordinators: Georg Griesinger (Germany)Course description: Ovarian stimulation remains an essential part of ART. Inter-individual variation in ovarianresponse represents a significant clinical and economical challenge. Undoubtedly, there is a need to reliably predictovarian response to stimulation, to tailor stimulation protocols optimizing the probability of pregnancy and keep at thesame time the risks of complications and costs at a minimum.Special emphasis needs to be given on how to avoid excessive response and predict the occurrence of ovarianhyperstimulation syndrome (OHSS), as well as on maximizing tolerability of treatment from a patient’s perspective.Topics to be covered include ovarian stimulation strategies; primary, secondary and tertiary prevention of OHSS;development of protocols for patients with diminished ovarian reserve; ovarian reserve testing and its practicalimplications; mild stimulation and financial implications; segmentation of IVF treatment; impact of ovarian stimulationon the endometrium; and emergency stimulation for oncofertility patients.Target audience: Physicians and scientists in reproductive medicineCourse type: AdvancedCourse <strong>programme</strong>SESSION 1: Cost IMPLICATIONS of OVARIAN STIMULATION in EXPECTED normal respondersChairman: Daniela Romualdi (Italy)09.00 - 09.15 Introduction and E-system voting09.15 - 09.45 Conventional stimulation & cryopreservation of surplus oocytes or embryos is the most costeffectivetreatment - Filippo Ubaldi (Italy)09.45 - 10.15 Repetitive natural cycles or mild stimulation offer most benefit per Euro spent -Michael von Wolff (Germany)10.15 - 10.30 E-system voting & Discussion10.30 - 11.00 Coffee breakSESSION 2: Poor response TO OVARIAN STIMULATION: three short SKETCHES and a mini-DEBATEChairman: Frank J. Broekmans (The Netherlands)11.00 - 11.15 Is the clinical impact of a poor response female age dependant? - Simone Broer (The Netherlands)11.15 - 11.30 Is manipulating intra-ovarian androgen conditions effective in upgrading ovarian response? -Renato Fanchin (France)11.30 - 11.45 Will application of stimulation dosages over 225 IU per day prevent a poor response? -Frank J. Broekmans (The Netherlands)11.45 - 12.30 Mini - Debate: A first cycle poor responder after adequate FSH dosing should not be allowedfurther ART treatment11.45 - 12.00 Pro - Petra De Sutter (Belgium)12.00 - 12.15 Con - Pia Saldeen (Sweden)12.15 - 12.30 E-system voting12.30 - 13.30 Lunch38
PRE-CONGRESS COURSESSession 3: Excessive responseChairman: Georg Griesinger (Germany)13.30 - 13.40 Introduction and E-system voting13.40 - 14.00 How should we stimulate patients with polycystic ovaries - Efstratios Kolibianakis (Greece)14.00 - 15.00 Debate: Excessive ovarian response affects oocyte quality, endometrial receptivityand child health14.00 - 14.22 Pro - Nicholas Macklon (United Kingdom)14.22 - 14.44 Con - Karin Middelburg (The Netherlands)14.45 - 15.00 E-system voting & Discussion15.00 - 15.30 Coffee breakSESSION 4: INDIVIDUALISATION of OVARIAN STIMULATION: CAN it IMPACT the OUTCOME?Chairman: Efstratios Kolibianakis (Greece)15.30 - 15.45 Introduction and E-system voting15.45 - 16.15 Maximising success rates by stimulation individualization -Ernesto Sr. Bosch (Spain)16.15 - 16.45 Individualisation of ovarian stimulation has little impact on outcome -Georg Griesinger (Germany)16.45 - 17.00 E-system voting & DiscussionProgramme book39
Page 1: London - United Kingdom 7 to 10 Jul
Page 9 and 10: Contents007 Welcome009 Committees01
Page 11: Session 48:Session 49:Session 50:Se
Page 18 and 19: Committee of National Representativ
Page 23 and 24: GENERAL INFORMATION−−Political
Page 25 and 26: Greater London is served by 12 Tube
Page 27: GENERAL INFORMATIONProgramme book17
Page 32 and 33: Monday 8 July 201308.00 - 17.30 IFF
Page 35 and 36: Agenda of the 2013 Annual GeneralAs
Page 37: AGENDAProgramme book25
Page 41: SOCIAL PROGRAMMEOpening Ceremony an
Page 44 and 45: COURSE 1Sunday, 7 July−−Room Ca
Page 46 and 47: Chairman: Willem Ombelet (Belgium)1
Page 48 and 49: New thoughtsChairman: Mariette Godd
Page 58 and 59: COURSE 11Sunday, 7 July−−Room C
Page 60 and 61: course 12Sunday, 7 July−−Room C
Page 62 and 63: Course 13Sunday, 7 July−−Room C
Page 64 and 65: course 15Sunday, 7 JulyRoom Capital
Page 66 and 67: Overview MONDAY, 8 July 201308.00 -
Page 68 and 69: Monday 8 July 2013Invited session08
Page 70 and 71: Monday 8 July 2013Selected oral com
Page 80 and 81: Monday 8 July 2013Company symposium
Page 92 and 93: Overview TUESDAY, 9 July 201308.30
Page 94 and 95: Tuesday 9 July 2013Invited session0
Page 96 and 97: Tuesday 9 July 2013Invited session0
Page 98 and 99: Tuesday 9 July 2013Selected oral co
Page 100 and 101: Tuesday 9 July 2013Selected oral co
Page 102 and 103:
Tuesday 9 July 2013Selected oral co
Page 104 and 105:
Tuesday 9 July 2013Company symposiu
Page 106 and 107:
Tuesday 9 July 2013Invited session1
Page 108 and 109:
Tuesday 9 July 2013Company symposiu
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Overview Wednesday, 10 July 201308.
Page 128 and 129:
Wednesday 10 July 2013Invited sessi
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Wednesday 10 July 2013Selected oral
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
136
Page 152 and 153:
Tuesday, 10 July13.00 P-050 Health
Page 154 and 155:
POSTERSAndrologyP-001 Magnetic Acti
Page 156 and 157:
P-028 Female age and number of retr
Page 158 and 159:
P-054 Genomic rearrangements and CN
Page 160 and 161:
P-079 A modified cryotop vitrificat
Page 162 and 163:
P-109 Effect of early blastomere mu
Page 164 and 165:
P-138 Cyclin E1 as a new ICM marker
Page 166 and 167:
P-167 Single medium culture in a ti
Page 168 and 169:
P-196 Early cleaving mouse embryos
Page 170 and 171:
P-225 Luteal phase support has a be
Page 172 and 173:
P-252 Correlation of histomorpholgy
Page 174 and 175:
P-283 Homologous intrauterine insem
Page 176 and 177:
P-310 Uterine contraction after emb
Page 178 and 179:
Paramedical - laboratoryP-335 To en
Page 180 and 181:
P-363 Effects of pharmacologically
Page 182 and 183:
P-393 "It is not his child, it is o
Page 184 and 185:
P-420 Differences in somatic cell g
Page 186 and 187:
P-446 Comparison between fresh or v
Page 188 and 189:
P-475 Use of ovarian reserve parame
Page 190 and 191:
P-503 Low follicular fluid tyrosine
Page 192 and 193:
P-531 Addition of luteal estradiol
Page 194 and 195:
P-557 Altered sensitivity rather th
Page 196 and 197:
P-585 A late presentation of obstru
Page 198 and 199:
184
Page 200 and 201:
Anastácio A. 60Andersen A.N. 80And
Page 202 and 203:
Bowman N. 55, 153Boyer P. 147Bozdag
Page 204 and 205:
Critchley H.O.D. 167Crivello A.M. 1
Page 206 and 207:
Farrag A. 143Farreras A. 149, 150Fa
Page 208 and 209:
Guarneri C. 143Gudi A. 57Guérif F.
Page 210 and 211:
Izzi-Engbeaya C. 177Izzo C.R. 148JJ
Page 212 and 213:
Kuchenbecker W.K.H. 182Kuchiki M. 1
Page 214 and 215:
Makedos A. 179Makyan Z. 134Malcov M
Page 216 and 217:
Nascimento A.M. 58, 73, 143,160, 17
Page 218 and 219:
Piccinini C.A. 166Piccolomini M. 17
Page 220 and 221:
Sanad A. 182Sanchez A.M. 158Sánche
Page 222 and 223:
Surlan L. 152, 164Sutcliffe A.G. 10
Page 224 and 225:
Velthut-Meikas A. 170Veltman D.J. 5
Page 226 and 227:
Zervomanolakis I. 87Zeyneloglu H.B.
Page 228:
Achevé d’imprimer par :
show all

Final programme - eshre 2013

Create successful ePaper yourself

Delete template?

Save as template?